$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
曲美替尼可作为复发性低级别浆液性卵巢癌的新标准护理选择
2025-10-19 11:44:20
Check Details
卢卡帕利的临床试验数据和安全性怎么样?
2025-10-19 11:44:20
Check Details
卢卡帕利是什么药?卢卡帕利怎么服用?
2025-10-19 11:44:20
Check Details
卵巢癌靶向药PARP抑制剂—尼拉帕尼Niraparib
2025-10-19 11:44:20
Check Details
奥拉帕尼Olaparib维持治疗可改善患者的无进展生存期
2025-10-19 11:44:20
Check Details
奥拉帕尼的生存期数据和副作用有哪些?
2025-10-19 11:44:20
Check Details
治疗卵巢癌的新药PARP抑制剂尼拉帕尼!
2025-10-19 11:44:20
Check Details
靶向治疗卵巢癌的PARP抑制剂奥拉帕尼疗效怎么样?
2025-10-19 11:44:20
Check Details
卢卡帕利的适应症是什么?该怎么使用?
2025-10-19 11:44:20
Check Details
奥拉帕尼正确的使用方法以及推荐剂量是多少?
2025-10-19 11:44:20
Check Details
尼拉帕利副作用及处理
2025-10-19 11:44:20
Check Details
奥拉帕尼有哪些副作用?
2025-10-19 11:44:20
Check Details
1
2
...
6975
6976
6977
6978
6979
6980
6981
...
10233
10234
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Hibsago (Bepirovirsen) Japan Approval: CHB Functional Cure and B-Well Data Essentials
2
FDA Approves Isembyld (apitegromab-mstn), the World’s First Skeletal Muscle-Targeted Therapy for SMA
3
Post-Enzalutamide mCRPC: HRR/PARP, PSMA Radioligand, and Chemotherapy Sequencing
4
Ceritinib for ALK-Positive NSCLC: Indication, Dosing, and Safety Management
5
Acalabrutinib in CLL/SLL Survival Expectation: ELEVATE-TN and ASCEND Long-Term PFS, OS
6
Bosutinib for CML: Time to Response, BCR-ABL Monitoring, and Molecular Remission
7
Bedaquiline for Drug-Resistant TB: 24-Week Regimen, Combination Duration, and When to Stop or Extend
8
Acalabrutinib Dosing and Combination Regimens: CLL/SLL, MCL, Safety Adjustments
9
Enzalutamide for Prostate Cancer: Managing Fatigue, Dizziness, Hypertension, and Serious Neurocardiovascular Risks
10
Bosutinib for Ph+ CML: Indications, Dosing Adjustments, and Hepatic/Renal Safety
11
Tamoxifen Long-Term Safety: Vigilance for Thrombosis and Endometrial Risks
12
Acoramidis for ATTR-CM: Disease Progression Is Not Equivalent to Drug Resistance